Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection Read more about Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer Read more about Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) Read more about A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome Read more about Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread Read more about Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Comparing Two Methods to Follow Patients With Pancreatic Cysts Read more about Comparing Two Methods to Follow Patients With Pancreatic Cysts
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer Read more about BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Read more about Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Read more about Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies Read more about Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies